Have a feature idea you'd love to see implemented?
Let us know!
NRXP NRX Pharmaceuticals Inc
Price (delayed)
$1.23
Market cap
$14.88M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.14
Enterprise value
$19.9M
Big Rock Partners is a blank check company formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination
Highlights
NRXP's EPS has surged by 58% year-on-year and by 22% since the previous quarter
NRX Pharmaceuticals's net income has increased by 43% YoY and by 18% from the previous quarter
NRX Pharmaceuticals's quick ratio has plunged by 83% YoY
The company's equity fell by 2.3% QoQ
Key stats
What are the main financial stats of NRXP
Market
Valuations
Earnings
Shares outstanding
12.09M
Market cap
$14.88M
Enterprise value
$19.9M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$20.07M
EBITDA
-$20.07M
Free cash flow
-$11.73M
Per share
Balance sheet
Liquidity
EPS
-$2.14
Free cash flow per share
-$1.07
Book value per share
-$1.73
Revenue per share
$0
TBVPS
$0.41
Total assets
$4.46M
Total liabilities
$23.28M
Debt
$6.67M
Equity
-$18.82M
Working capital
-$16.19M
Debt to equity
-0.35
Current ratio
0.2
Quick ratio
0.08
Net debt/EBITDA
-0.25
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-391.6%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NRXP stock price
How has the NRX Pharmaceuticals stock price performed over time
Intraday
1.65%
1 week
6.03%
1 month
-0.81%
1 year
-58.16%
YTD
-73.26%
QTD
-27.22%
Financial performance
How have NRX Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$20.48M
Net income
-$20.38M
Gross margin
N/A
Net margin
N/A
NRX Pharmaceuticals's net income has increased by 43% YoY and by 18% from the previous quarter
The operating income has grown by 39% YoY and by 12% from the previous quarter
Growth
What is NRX Pharmaceuticals's growth rate over time
Valuation
What is NRX Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NRXP's EPS has surged by 58% year-on-year and by 22% since the previous quarter
The company's equity fell by 2.3% QoQ
Efficiency
How efficient is NRX Pharmaceuticals business performance
NRX Pharmaceuticals's ROA has plunged by 119% YoY and by 16% from the previous quarter
Dividends
What is NRXP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NRXP.
Financial health
How did NRX Pharmaceuticals financials performed over time
The total assets is 81% less than the total liabilities
NRX Pharmaceuticals's quick ratio has plunged by 83% YoY
NRX Pharmaceuticals's current ratio has plunged by 71% YoY and by 4.8% from the previous quarter
NRX Pharmaceuticals's debt is 135% more than its equity
The debt to equity has soared by 78% YoY and by 26% from the previous quarter
NRX Pharmaceuticals's debt has decreased by 34% YoY and by 22% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.